BVMFBLAU3
Market cap390mUSD
Dec 23, Last price
13.60BRL
1D
-3.20%
1Q
1.19%
IPO
-65.45%
Name
Blau Farmaceutica SA
Chart & Performance
P/E
9.67
P/S
1.76
EPS
1.41
Div Yield, %
2.74%
Shrs. gr., 5y
0.27%
Rev. gr., 5y
11.91%
Revenues
1.37b
-2.44%
Net income
250m
-31.25%
CFO
188m
+9.40%
Dividend
Sep 27, 20240.08442108 BRL/sh
Profile
Blau Farmacêutica S.A., a pharmaceutical company provides private label drugs in Brazil, Argentina, Colombia, the United States, Ecuador, Peru, and Uruguay. The company's medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics. It also offers biological drugs; oral and injectable drugs for treating cancer; specialized treatments for infectious diseases; and prescription and non-prescription drugs, including dermo-medicines, condoms, and others for retail and non-retail markets. In addition, the company provides blood-derived, biological, biotechnological, and antiretroviral drugs. It serves hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions. The company was incorporated in 1987 and is headquartered in Cotia, Brazil.
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,372,633 -2.44% | 1,406,909 2.96% | 1,366,407 15.62% | ||||||
Cost of revenue | 1,177,613 | 991,792 | 954,360 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 195,020 | 415,117 | 412,047 | ||||||
NOPBT Margin | 14.21% | 29.51% | 30.16% | ||||||
Operating Taxes | 86,742 | 108,068 | 158,604 | ||||||
Tax Rate | 44.48% | 26.03% | 38.49% | ||||||
NOPAT | 108,278 | 307,049 | 253,443 | ||||||
Net income | 249,809 -31.25% | 363,368 11.73% | 325,222 27.87% | ||||||
Dividends | (66,162) | (135,523) | (104,134) | ||||||
Dividend yield | 2.29% | 2.96% | 1.69% | ||||||
Proceeds from repurchase of equity | (17,838) | (121,603) | 1,189,943 | ||||||
BB yield | 0.62% | 2.65% | -19.35% | ||||||
| Debt | |||||||||
Debt current | 75,018 | 79,870 | 91,552 | ||||||
Long-term debt | 571,839 | 260,015 | 291,319 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 63,195 | 81,829 | 69,300 | ||||||
Net debt | (25,647) | (303,762) | (539,994) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 188,060 | 171,903 | 153,976 | ||||||
CAPEX | (264,392) | (180,135) | (177,772) | ||||||
Cash from investing activities | (356,774) | 132,963 | (870,323) | ||||||
Cash from financing activities | 186,095 | (342,616) | 698,014 | ||||||
FCF | (240,204) | (84,631) | (111,153) | ||||||
| Balance | |||||||||
Cash | 407,314 | 643,647 | 922,822 | ||||||
Long term investments | 265,190 | 43 | |||||||
Excess cash | 603,872 | 573,302 | 854,545 | ||||||
Stockholders' equity | 2,038,140 | 1,857,829 | 1,634,885 | ||||||
Invested Capital | 2,063,110 | 1,634,503 | 1,222,048 | ||||||
ROIC | 5.86% | 21.50% | 24.87% | ||||||
ROCE | 6.98% | 18.80% | 19.84% | ||||||
| EV | |||||||||
Common stock shares outstanding | 177,681 | 179,394 | 179,394 | ||||||
Price | 16.24 -36.41% | 25.54 -25.50% | 34.28 | ||||||
Market cap | 2,885,539 -37.02% | 4,581,723 -25.50% | 6,149,626 | ||||||
EV | 2,853,677 | 4,273,739 | 5,608,228 | ||||||
EBITDA | 233,909 | 437,402 | 432,957 | ||||||
EV/EBITDA | 12.20 | 9.77 | 12.95 | ||||||
Interest | 37,583 | 32,431 | 26,796 | ||||||
Interest/NOPBT | 19.27% | 7.81% | 6.50% | ||||||